$13,592.15 speaking Payment -- Teva Pharmaceuticals to Dr. Amanda Lewis
Pain Management Physician Receives Over $13,000 for Speaking Engagement on Imbruvica
This page provides a detailed analysis of a $13,592.15 speaking payment from Teva Pharmaceuticals to Dr. Amanda Lewis. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $13,592.15 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Teva Pharmaceuticals |
| Physician | Dr. Amanda Lewis |
| NPI Number | 1469227036 |
| Physician Specialty | Pain Management |
| Location | Houston, TX |
| Date of Payment | 2024-09-16 |
| Related Drug/Device | Imbruvica |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Teva Pharmaceuticals made a $13.6K speaking payment to Amanda Lewis, a Pain Management specialist in Houston, TX. The payment was associated with Imbruvica. The payment of $13,592.15 to Dr. Amanda Lewis from Teva Pharmaceuticals is for speaking engagements. This payment is associated with the drug Imbruvica, indicating a focus on its promotion or education. The payment occurred on September 16, 2024, and was made to a physician in Houston, TX.
Patient Guidance: What This Payment Means for You
If you are a patient, this information shows that your doctor may receive compensation for educating others about medications like Imbruvica. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements can vary widely, but this amount for a single engagement may be on the higher end for a Pain Management specialist.
Regulatory Context: Sunshine Act Requirements
This payment is reportable under the Sunshine Act, which requires disclosure of payments made by manufacturers of drugs and medical devices to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-engagement
- physician-payment
- pharmaceutical-industry
- pain-management
- drug-promotion
- tevapharmaceuticals
- imbruvica
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $13.6K payment for?
This was a speaking payment of $13.6K from Teva Pharmaceuticals to Amanda Lewis, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Imbruvica. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Amanda Lewis accept pharmaceutical money?
Yes, Amanda Lewis received this $13.6K payment from Teva Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amanda Lewis's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $13.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Pain Management?
To compare this payment against Pain Management averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pain Management physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Amanda Lewis's relationship with Teva Pharmaceuticals?
The payment amount is substantial, suggesting significant time and expertise were involved in the speaking engagement. This $13.6K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Pain Management?
The nature of the payment, 'Compensation for serving as faculty or as a speaker,' is clearly defined.
What should patients do after learning about this payment?
If you are a patient, this information shows that your doctor may receive compensation for educating others about medications like Imbruvica.
What else should I know about this speaking payment?
The specific drug, Imbruvica, is mentioned, providing insight into the topic of the speaking engagement.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.